Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Inflammatory Bowel Disease II: Crohn's Disease01:30

Inflammatory Bowel Disease II: Crohn's Disease

1.6K
Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
1.6K
Inflammatory Bowel Disease I: Ulcerative Colitis01:27

Inflammatory Bowel Disease I: Ulcerative Colitis

1.5K
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
1.5K
Chronic Bowel Disorders: Introduction01:17

Chronic Bowel Disorders: Introduction

950
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
950
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy01:30

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

1.1K
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
1.1K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

804
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
804
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

991
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
991

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

An enlightening lesson on the physician-patient relationship by Voltaire.

The American journal of medicine·2025
Same author

Biologic therapy plus oral oxybutynin chloride in hidradenitis suppurativa: A potentially valid therapy to moderate acute flares.

Journal of the American Academy of Dermatology·2025
Same author

Real-life effectiveness and safety of baricitinib in patients with severe alopecia areata: A 24-week Italian study.

Journal of the European Academy of Dermatology and Venereology : JEADV·2024
Same author

Effectiveness of guselkumab in patients with facial and/or genital psoriasis: Interim analysis results at Week 12 from the GULLIVER study.

Journal of the European Academy of Dermatology and Venereology : JEADV·2024
Same author

Gender differences in adult atopic dermatitis and clinical implication: Results from a nationwide multicentre study.

Journal of the European Academy of Dermatology and Venereology : JEADV·2023
Same author

Potential drug-drug interactions with mitogen-activated protein kinase (MEK) inhibitors used to treat melanoma.

Expert opinion on drug metabolism & toxicology·2023

Related Experiment Video

Updated: Apr 15, 2026

Chronic Salmonella Infection Induced Intestinal Fibrosis
08:40

Chronic Salmonella Infection Induced Intestinal Fibrosis

Published on: September 22, 2019

7.7K

Cutaneous vasculitis and inflammatory bowel diseases.

O Simonetti1, V Postacchini, A Offidani

  • 1Clinic of Dermatology, Department of Clinical and Molecular Sciences, Università Politecnica delle Marche, Ancona, Italy - o.simonetti@univpm.it.

Giornale Italiano Di Dermatologia E Venereologia : Organo Ufficiale, Societa Italiana Di Dermatologia E Sifilografia
|April 2, 2015
PubMed
Summary

Up to 40% of inflammatory bowel disease (IBD) patients experience extraintestinal manifestations, including rare but significant cutaneous vasculitides. This review details their clinical presentation and underlying mechanisms, especially concerning biological therapies.

More Related Videos

Evaluating Therapeutic Interventions in the SHIP-deficient Mouse Model of Crohn Disease-like Ileitis and Fibrosis
09:44

Evaluating Therapeutic Interventions in the SHIP-deficient Mouse Model of Crohn Disease-like Ileitis and Fibrosis

Published on: October 14, 2025

613
A TNBS-Induced Rodent Model to Study the Pathogenic Role of Mechanical Stress in Crohn's Disease
05:08

A TNBS-Induced Rodent Model to Study the Pathogenic Role of Mechanical Stress in Crohn's Disease

Published on: March 1, 2022

4.7K

Related Experiment Videos

Last Updated: Apr 15, 2026

Chronic Salmonella Infection Induced Intestinal Fibrosis
08:40

Chronic Salmonella Infection Induced Intestinal Fibrosis

Published on: September 22, 2019

7.7K
Evaluating Therapeutic Interventions in the SHIP-deficient Mouse Model of Crohn Disease-like Ileitis and Fibrosis
09:44

Evaluating Therapeutic Interventions in the SHIP-deficient Mouse Model of Crohn Disease-like Ileitis and Fibrosis

Published on: October 14, 2025

613
A TNBS-Induced Rodent Model to Study the Pathogenic Role of Mechanical Stress in Crohn's Disease
05:08

A TNBS-Induced Rodent Model to Study the Pathogenic Role of Mechanical Stress in Crohn's Disease

Published on: March 1, 2022

4.7K

Area of Science:

  • Dermatology
  • Gastroenterology
  • Immunology

Background:

  • Extraintestinal manifestations affect up to 40% of inflammatory bowel disease (IBD) patients.
  • Cutaneous vasculitides are rare but significant manifestations in IBD, impacting morbidity and diagnosis.
  • Biological therapies for IBD may influence the development of vascular disorders.

Purpose of the Study:

  • To provide a comprehensive review of cutaneous vasculitides in IBD patients.
  • To focus on the clinical presentation of these conditions.
  • To explore potential pathophysiological mechanisms.

Main Methods:

  • Literature review of studies on IBD and cutaneous vasculitides.
  • Analysis of clinical presentations and diagnostic challenges.
  • Discussion of etiological factors, including biological therapies.

Main Results:

  • Cutaneous vasculitides can precede gastrointestinal symptoms in IBD.
  • These conditions represent a diagnostic challenge and a cause of morbidity.
  • Biological therapies may be implicated in the pathogenesis of vascular issues.

Conclusions:

  • Understanding cutaneous vasculitides is crucial for managing IBD patients.
  • Further research into pathophysiological mechanisms is warranted.
  • Clinical vigilance for vasculitic manifestations in IBD is essential.